Over the last 10 years, every aspect of continuing medical education (CME) has endured major changes, forcing several pharmaceutical companies to reassess their future position in this important industry sector. Consider these facts:Pharma company financial support for CME in the US has fallen for the fourth year in a row: from $1.2 billion in 2007 to $736 million in 2011; to minimise CME risks, many large pharma companies have stopped funding CME projects executed by commercial providers, and others are following suit; outside the US, an increasing number of pharma companies are now aligning their investments with independent medical education (IME); and stricter CME guidelines in the US and Europe are prompting more companies to hand over budgetary control to regulatory teams.
So what role could or should the pharmaceutical industry play in medical education for healthcare professionals? And what should it expect in return for its investments? Find out in one convenient, compelling FirstWord Dossier report: Pharma’s Future Role in CME.
Key features of Pharma’s Future Role in CME include:
- Recent and expected US and European CME regulations
- Latest pharma approaches to minimising risk in CME
- Growing use of independent medical education (IME)
- Comparative differences between CME vs IME
- Potential effects of CME funding from other providers
- Key factors affecting future pharma investment in CME
- Opportunities in eCME and online medical education
- Internal pharma company changes for managing CME
Save time and effort by reviewing forecasts from 10 leading figures in the US and European CME fields. In this report, they analyse the emerging trends, radical changes, and major risks affecting future medical education. These opinion leaders also examine whether it would be better for the industry to take a leading role in future CME productions, or strategically direct these from the background.. This report will help you to:
- Understand the issues affecting CME in US and Europe
- Review your future CME, IME and eCME options
- Assess other medical education funding sources
- Evaluate the quality and efficacy of your CME content
- Explore the benefits of eCME for physicians and pharma
- Identify your company’s ultimate goal for CME programs
- Start planning your next medical education strategies
- Improve your potential medical education outcomes
Pharma’s Future Role in CME answers key questions including:
- What are the primary factors affecting US and European CME?
- How are medical education providers having to adapt?
- Should physicians be responsible for funding their own CME?
- What are the key differences between CME and IME?
- What ROI can pharma expect from IME investments?
- Could eCME take over from face-to-face CME?
- Who should be managing internal pharma CME budgets?
- What do physicians think about the quality of CME content?
”I hope that we will find how to have similar rules all over the world. The big problem nowadays is that you have different rules in the US, in Canada, in Europe, in different Member States. It makes it very difficult because how can you comply with all the legislations?” Dr Bernard Maillet, treasurer, VBS-GBS
“Everyone should take a long hard look at the dollars they're investing in CME, and why they're investing it. If their answer is to sell more products then they shouldn’t be in it. If their answer is to improve patient care then they’re in the right place,” Maureen Doyle-Scharff, Senior Director, Medical Education Group, Pfizer
“Currently several pharmaceutical companies are aligning themselves to IME education. Some companies are grouping CME and IME together,” David Noble, Global Head, PeerVoice
“The absolute critical thing that must happen with pharma is the budgets for CME must be taken away from marketing. The top 10 pharma companies are set up to hand over money from the marketing department to [regulations and legal departments],” Eugene Pozniak, programme director, European CME Forum